Intrinsiqq
Kyverna Therapeutics, Inc. logo

Kyverna Therapeutics, Inc. Financials

KYTX

⊜ Compare

All currency values in $ millions unless otherwise noted

Income Statement
DEC 2025
DEC 2024
57:1 split
DEC 2023
General & Administrative$36$30$12
Research & Development$134$112$50
Total Operating Expenses$170$143$62
Operating Income-$170-$143-$62
Non-Operating
Net Interest Expense$9$15$2
Other Non-Operating Income (Expense)$9$15$2
Income Tax Expense$0$0$0
Net Income
Net Income-$161-$127-$60
EPS (Basic)-$3.64-$3.33-$89.61
EPS (Diluted)-$3.64-$3.33-$89.61
Weighted Avg Shares (Basic)44.3M38.3M673,622
Weighted Avg Shares (Diluted)44.3M38.3M673,622
Shares Outstanding44.3M38.3M673,622

Kyverna Therapeutics (KYTX) financials: revenue, profit and margins

Kyverna Therapeutics (KYTX) generated about n/a in revenue and -$153 million in net income over the trailing twelve months. Figures are from SEC filings; this is analysis, not investment advice.

Frequently asked

Is Kyverna Therapeutics profitable?+

Kyverna Therapeutics reported about -$153 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.

How the market compares: How many US companies are profitable

SourceFinancial statements computed from the 10-Q filed 3 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 12 Aug 2026. How this is calculated.

Fiscal year ends Dec.

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with KYTX

CompareIntrinsic value
LENZLENZ Therapeutics, Inc.
$3.46-1.14%10
PROKProKidney Corp
$1.12+4.67%10
MGXMetagenomi, Inc.
$0.79+3.95%10
PALIPalisade Bio Inc.
$1.25+1.63%20
ENTXEntera Bio Ltd.
$3.11+1.97%20
ELOXEloxx Pharmaceuticals, Inc.
$12.74-1.39%20
CMPXCompass Therapeutics Inc.
$0.76+1.33%10
SABSSab Biotherapeutics Inc.
$3.18+1.92%19

Held by ETFs

KYTX is in 14 US ETFs. The largest of them, with KYTX's weight in each:

Spot a number that looks wrong? Check it in KYTX's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing KYTX

Create a free account and get 14 days of Premium: every stock and every tool.

  • Unlimited stocks
  • Stock screener
  • Portfolio tracker
  • Editable DCF
  • Compare side by side
  • Unlimited alerts

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.